Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Hong Kong
/
Pharmaceuticals & Biotech
Create a narrative
Pharmaceuticals & Biotech Community
Our community narratives are driven by numbers and valuation.
Create a narrative
All companies
Popular
Undervalued
Overvalued
Pharmaceuticals & Biotech Investing Ideas
Genscript Biotech
AN
AnalystConsensusTarget
Consensus Narrative from 9 Analysts
Global Demand Rebound Will Drive Life Sciences And CDMO Expansion
Key Takeaways Expansion in global markets, technology upgrades, and industry partnerships are set to drive stronger growth, improved margins, and long-term earnings stability. Increased outsourcing trends and customer diversification protect against risk and create reliable revenue streams for future financial performance.
View narrative
HK$21.61
FV
16.0% undervalued
intrinsic discount
15.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
6855
Ascentage Pharma Group International
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
Takeda Deal And Olverembatinib Trials Will Open Global Markets
Key Takeaways Ascentage's strategic alliances and NRDL inclusion are set to enhance market reach, boost accessibility, and drive substantial revenue growth. Successful NASDAQ IPO and promising registrational trials position the company to accelerate pipeline development, enhancing future earnings potential.
View narrative
HK$60.36
FV
22.1% overvalued
intrinsic discount
20.82%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
Everest Medicines
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
NRDL Approval And Pipeline Efforts Will Counterbalance Potential Risks
Key Takeaways Dependence on NEFECON's success and market strategies in the IgAN space may not deliver the expected revenue, posing financial risks. Heavy investments in sales and R&D could strain margins if they fail to generate proportional revenue growth, impacting near-term earnings.
View narrative
HK$48.14
FV
46.9% overvalued
intrinsic discount
68.86%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
6 days ago
author updated this narrative
WuXi Biologics (Cayman)
AN
AnalystLowTarget
Consensus Narrative from 26 Analysts
Escalating Geopolitical And Regulatory Risks Will Disrupt CDMO Markets
Key Takeaways Geopolitical tensions and regulatory scrutiny threaten WuXi Biologics' access to key global markets, undermining revenue stability and growth prospects. Supply chain localization trends and intensified competition risk reducing facility utilization, increasing pricing pressure, and eroding both margins and earnings visibility.
View narrative
HK$20.18
FV
42.5% overvalued
intrinsic discount
14.47%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
7 days ago
author updated this narrative
Akeso
AN
AnalystLowTarget
Consensus Narrative from 20 Analysts
Aggressive Pricing In China Will Compress Margins Despite Clinical Promise
Key Takeaways Deep price cuts and increased government cost controls are set to compress Akeso's revenue, margins, and profitability for the foreseeable future. Heavy pipeline concentration and escalating competition expose Akeso to significant growth risk and potential shareholder dilution.
View narrative
HK$89.52
FV
60.2% overvalued
intrinsic discount
47.01%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
7 days ago
author updated this narrative
WuXi Biologics (Cayman)
AN
AnalystConsensusTarget
Consensus Narrative from 26 Analysts
Ireland, US And Singapore Facilities Will Transform Pharmaceutical Pipeline
Key Takeaways Strong pipeline and commercial manufacturing expansion signal robust future revenue growth and enhanced earnings potential in pharmaceutical sectors. International expansion and innovative platforms aim to boost margins and profits through efficiencies and high-margin intellectual property revenues.
View narrative
HK$28.30
FV
1.6% overvalued
intrinsic discount
14.54%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
7 days ago
author updated this narrative
WuXi Biologics (Cayman)
AN
AnalystHighTarget
Consensus Narrative from 26 Analysts
Global Biologics Demand Will Drive CDMO Expansion Worldwide
Key Takeaways Strong late-stage project wins, innovative platforms, and industry-leading client retention are fueling accelerated revenue growth and boosting profit margins ahead of competitors. Regulatory complexities and market consolidation favor WuXi Biologics, enabling enhanced market share, pricing power, and resilience against competitive and operational risks.
View narrative
HK$40.44
FV
28.9% undervalued
intrinsic discount
20.68%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
9 days ago
author updated this narrative
Akeso
AN
AnalystHighTarget
Consensus Narrative from 20 Analysts
Breakthrough Immunotherapies And Aging Trends Will Revitalize Global Oncology
Key Takeaways Explosive product uptake and rapid expansion in hospital coverage could drive revenue growth much faster than market expectations. Broad pipeline successes and strong government support position Akeso as a global leader in oncology and innovative biologics with significant future market share potential.
View narrative
HK$141.33
FV
1.5% overvalued
intrinsic discount
74.21%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
9 days ago
author updated this narrative
InnoCare Pharma
AN
AnalystConsensusTarget
Consensus Narrative from 9 Analysts
Orelabrutinib Commercialization And ADC Pipeline Will Open New Markets
Key Takeaways Strong progress in drug commercialization and pipeline development suggests significant potential for future revenue growth and enhanced earnings. Strategic global expansion and innovative therapies aim to improve net margins and drive long-term revenue stability.
View narrative
HK$12.25
FV
45.1% overvalued
intrinsic discount
33.33%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
14 days ago
author updated this narrative
Value any company in seconds
Popular companies